Walnuts for Power: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and Energy

What is the Purpose of this Study?

This study focuses on patients who have been diagnosed with prostate cancer and plan to undergo radical prostatectomy (surgery to remove the prostate gland and surrounding tissues). The purpose of the study is to examine the effects of daily walnut intake on the growth of prostate cancer by measuring changes in the proliferative index (an indicator of disease severity) in biopsy and surgical tissue. The proliferative index is a measure of the number of cells in a tumor that are dividing, which can indicate how fast a tumor is growing. Researchers aim to determine whether daily walnut consumption will slow prostate cancer growth compared to no daily walnut consumption in men with prostate cancer who are scheduled to undergo radical prostatectomy.

Participants will be randomly assigned to one of two study groups. The first group will be asked to consume 2 ounces of walnuts per day, in addition to their regular diet. The second group will follow their usual diet.


Eligibility

  • * Pathologically confirmed prostate adenocarcinoma.
  • * Diagnostic biopsy cores with ≥10 cores with each core examined separately to determine exact tumor location.
  • * Biopsy grade group 2 or higher (Gleason ≥7).
  • * Planning to undergo RP.
Show more

Where can I participate?

  • Cedars-Sinai Cancer at SOCC


More about this Clinical Trial

What is the full name of this clinical trial?

IIT2018-23-Freedland-POWR: WALNUTS for POWER: Polyphenols, Omega-3 fatty acids, Weight loss, and EneRgy

Study Details
Disease Type/Condition

Lifestyle, Prostate cancer

Principal Investigator

Freedland, Stephen

Co-Investigators

Edwin Posadas, Hyung Kim, Timothy Daskivich

Age Group

Adult

Phase

II

IRB Number

Pro00055792

ClinicalTrials.gov ID

NCT03824652

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Lifestyle, Prostate cancer

Principal Investigator

Freedland, Stephen

Age Group

Adult

Phase

II

IRB Number

IIT2018-23-FREEDLAND-POWR

ClinicalTrials.gov ID

NCT03824652

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org